Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | Suite 261, 2403 Sidney Street PITTSBURGH PA 15203 |
Tel: | N/A |
Website: | https://cogrx.com |
IR: | See website |
Key People | ||
Lisa R. Ricciardi President, Chief Executive Officer, Director | John Doyle Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer | Anthony Caggiano Chief Medical Officer, Head of R&D |
Business Overview |
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It is focused on developing a pipeline of small molecule product candidates that targets the sigma-2 receptor (S2R) complex, a key regulator of the cellular damage response for diseases, such as Alzheimer's disease (AD), dry age-related macular degeneration (dry AMD), geographic atrophy, and other conditions. The Company's lead product candidate, CT1812, is an orally delivered, small molecule modulator designed to penetrate the blood-brain barriers to the S2R complex, and through its modulation, S2R restores the normal function of synapses, as well as critical cellular processes, such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling lipid membrane-bound protein trafficking, and others. |
Financial Overview |
For the nine months ended 30 September 2023, Cognition Therapeutics Inc revenues was not reported. Net loss increased 9% to $17.6M. Higher net loss reflects Research & Development Expense - Balanci increase of 7% to $25.1M (expense), Stock-based Compensation in SGA increase of 23% to $2.8M (expense), Grant income decrease of 1% to $18M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.71 to -$0.59. |
Employees: | 22 as of Mar 1, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $38.01M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$44.74M as of Dec 31, 2023 |
Net annual income (TTM): | -$22.83M as of Dec 31, 2023 |
Free cash flow (TTM): | -$20.87M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 39,000,152 as of Mar 11, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |